Novel ultrafiltration technique for blood conservation in cardiac operations

Terry Gourlay, Serdar Gunaydin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The performance characteristics and clinical outcome of a novel
hemoconcentrator, the HemoSep (Brightwake, Nottingham, United Kingdom), for
reusing salvaged blood postoperatively were evaluated.
HemoSep concentrates blood by removing the fluid component from a
pooled volume of blood salvaged at the end of the operation from the heart-lung
machine. During a 6-month period, 102 patients were prospectively randomized into
two groups. In group 1 (n = 52), salvaged blood in the venous reservoir after the
cessation of cardiopulmonary bypass was reused by the HemoSep device and the
processed blood was retransfused to the patients. In group 2 (n = 50), the
control group, the operation proceeded using conventional method without using
the hemoconcentrator.
The mean amount of processed blood was 775 ± 125 mL. The efficacy of
the HemoSep device was confirmed by the percentage concentration of the
hematocrit at 15 and 40 minutes. Serum albumin and factor VII levels were
concentrated more than threefold at 40 minutes vs baseline measurements. Patients
who received processed blood had significantly less need for an allogeneic
transfusion.
The HemoSep device functions as designed and without technical
failures, offering a complementary technique in blood management during cardiac
operations.
LanguageEnglish
Pages2148-2151
Number of pages4
JournalAnnals of Thoracic Surgery
Volume95
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Ultrafiltration
Conservation
Blood
Equipment and Supplies
Vascular Access Devices
Factor VII
Blood Volume
Cardiopulmonary Bypass
Serum Albumin
Fluids

Keywords

  • autotransfusion
  • open-heart surgery
  • haemoconcentration
  • cardiopulmonary bypass

Cite this

@article{3cefbcd684f449d78ec8b770555eb8ec,
title = "Novel ultrafiltration technique for blood conservation in cardiac operations",
abstract = "The performance characteristics and clinical outcome of a novelhemoconcentrator, the HemoSep (Brightwake, Nottingham, United Kingdom), forreusing salvaged blood postoperatively were evaluated.HemoSep concentrates blood by removing the fluid component from apooled volume of blood salvaged at the end of the operation from the heart-lungmachine. During a 6-month period, 102 patients were prospectively randomized intotwo groups. In group 1 (n = 52), salvaged blood in the venous reservoir after thecessation of cardiopulmonary bypass was reused by the HemoSep device and theprocessed blood was retransfused to the patients. In group 2 (n = 50), thecontrol group, the operation proceeded using conventional method without usingthe hemoconcentrator.The mean amount of processed blood was 775 ± 125 mL. The efficacy of the HemoSep device was confirmed by the percentage concentration of thehematocrit at 15 and 40 minutes. Serum albumin and factor VII levels wereconcentrated more than threefold at 40 minutes vs baseline measurements. Patientswho received processed blood had significantly less need for an allogeneictransfusion.The HemoSep device functions as designed and without technicalfailures, offering a complementary technique in blood management during cardiacoperations.",
keywords = "autotransfusion, open-heart surgery, haemoconcentration, cardiopulmonary bypass",
author = "Terry Gourlay and Serdar Gunaydin",
year = "2013",
month = "6",
doi = "10.1016/j.athoracsur.2013.03.048",
language = "English",
volume = "95",
pages = "2148--2151",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier Inc.",
number = "6",

}

Novel ultrafiltration technique for blood conservation in cardiac operations. / Gourlay, Terry; Gunaydin, Serdar.

In: Annals of Thoracic Surgery, Vol. 95, No. 6, 06.2013, p. 2148-2151.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel ultrafiltration technique for blood conservation in cardiac operations

AU - Gourlay, Terry

AU - Gunaydin, Serdar

PY - 2013/6

Y1 - 2013/6

N2 - The performance characteristics and clinical outcome of a novelhemoconcentrator, the HemoSep (Brightwake, Nottingham, United Kingdom), forreusing salvaged blood postoperatively were evaluated.HemoSep concentrates blood by removing the fluid component from apooled volume of blood salvaged at the end of the operation from the heart-lungmachine. During a 6-month period, 102 patients were prospectively randomized intotwo groups. In group 1 (n = 52), salvaged blood in the venous reservoir after thecessation of cardiopulmonary bypass was reused by the HemoSep device and theprocessed blood was retransfused to the patients. In group 2 (n = 50), thecontrol group, the operation proceeded using conventional method without usingthe hemoconcentrator.The mean amount of processed blood was 775 ± 125 mL. The efficacy of the HemoSep device was confirmed by the percentage concentration of thehematocrit at 15 and 40 minutes. Serum albumin and factor VII levels wereconcentrated more than threefold at 40 minutes vs baseline measurements. Patientswho received processed blood had significantly less need for an allogeneictransfusion.The HemoSep device functions as designed and without technicalfailures, offering a complementary technique in blood management during cardiacoperations.

AB - The performance characteristics and clinical outcome of a novelhemoconcentrator, the HemoSep (Brightwake, Nottingham, United Kingdom), forreusing salvaged blood postoperatively were evaluated.HemoSep concentrates blood by removing the fluid component from apooled volume of blood salvaged at the end of the operation from the heart-lungmachine. During a 6-month period, 102 patients were prospectively randomized intotwo groups. In group 1 (n = 52), salvaged blood in the venous reservoir after thecessation of cardiopulmonary bypass was reused by the HemoSep device and theprocessed blood was retransfused to the patients. In group 2 (n = 50), thecontrol group, the operation proceeded using conventional method without usingthe hemoconcentrator.The mean amount of processed blood was 775 ± 125 mL. The efficacy of the HemoSep device was confirmed by the percentage concentration of thehematocrit at 15 and 40 minutes. Serum albumin and factor VII levels wereconcentrated more than threefold at 40 minutes vs baseline measurements. Patientswho received processed blood had significantly less need for an allogeneictransfusion.The HemoSep device functions as designed and without technicalfailures, offering a complementary technique in blood management during cardiacoperations.

KW - autotransfusion

KW - open-heart surgery

KW - haemoconcentration

KW - cardiopulmonary bypass

UR - http://dx.doi.org/10.1016/j.athoracsur.2013.03.048

U2 - 10.1016/j.athoracsur.2013.03.048

DO - 10.1016/j.athoracsur.2013.03.048

M3 - Article

VL - 95

SP - 2148

EP - 2151

JO - Annals of Thoracic Surgery

T2 - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -